AbbVie’s experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company.

The FDA started the blood tests to watch for the risk of severe neutropenia ... a monthly injection of a long-acting ...

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Swiss psychoanalyst Hermann Rorschach formalized this idea through the inkblot test he created—he noticed that people with schizophrenia tended to perceive the images differently than did other ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

An AbbVie schizophrenia drug acquired as part of a ... significantly lower than what was reported for Cobenfy’s Phase 3 test. The AbbVie drug’s studies also had higher placebo responses ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

In a study published November 7 in the journal Cell Reports Medicine, researchers from Tufts University School of Medicine ...

AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of ...